AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38185283 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction (T2MI)
Number of subjects: 194
Study 38185283 — intervention group
Group type: COMPARATOR
Intervention: Type 1 myocardial infarction (T1MI)
Number of subjects: 194
Study 38185283 — intervention group
Group type: EXPERIMENTAL
Intervention: T2MI
Number of subjects: 194
Study 38185496 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38185589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab monotherapy
Number of subjects: 71
Study 38185589 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 71
Study 38185589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus platinum-based chemotherapy
Number of subjects: 71
Study 38185589 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab plus platinum-based chemotherapy
Number of subjects: 71
Study 38185589 — intervention group
Group type: EXPERIMENTAL
Intervention: All sintilimab-treated patients
Number of subjects: 71
Study 38185589 — intervention group
Group type: COMPARATOR
Intervention: All pembrolizumab-treated patients
Number of subjects: 71
Study 38185589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 71
Study 38185589 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 71
Study 38185619 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversalis fascia plane block (TFPB)
Number of subjects: 80
Study 38185619 — intervention group
Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 80
Study 38185720 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-naïve BC patients
Number of subjects: 112
Study 38185720 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 112
Study 38185760 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoracheal intubation (OTI) during NMOSD-AQP4-IgG+ attacks
Number of subjects: 44
Study 38185870 — intervention group
Group type: EXPERIMENTAL
Intervention: KidneyIntelX test
Number of subjects: 5348
Study 38185882 — intervention group
Group type: EXPERIMENTAL
Intervention: CMRGlu classification model
Number of subjects: 19
Study 38185882 — intervention group
Group type: EXPERIMENTAL
Intervention: CBF classification model
Number of subjects: 19
Study 38185882 — intervention group
Group type: EXPERIMENTAL
Intervention: GMV classification model
Number of subjects: 19
Study 38185882 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multi-modal imaging classification model
Number of subjects: 19
Study 38185920 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopic Laser Lithotripsy
Number of subjects: 0
Study 38186268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0
Study 38186268 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 38186268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab biosimilar
Number of subjects: 0
Study 38186641 — intervention group
Group type: EXPERIMENTAL
Intervention: New long-acting insulin analog
Number of subjects: 0
Study 38186641 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38186705 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based eHealth intervention of cognitively demanding exercise for older adults
Number of subjects: 0
Study 38187149 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe anemia (Hb <11 g/dL for men and <10 g/dL for women)
Number of subjects: 470
Study 38187149 — intervention group
Group type: COMPARATOR
Intervention: No anemia (Hb ≥13 g/dL for men and ≥12 g/dL for women)
Number of subjects: 470
Study 38187149 — intervention group
Group type: COMPARATOR
Intervention: Mild anemia (Hb 11-13 g/dL for men and 10-12 g/dL for women)
Number of subjects: 470
Study 38187797 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual family counseling and participation in nutrition courses and physical activity groups
Number of subjects: 137
Study 38187863 — intervention group
Group type: EXPERIMENTAL
Intervention: Telazorlimab 300 mg every 2 weeks (part 1)
Number of subjects: 462
Study 38187863 — intervention group
Group type: EXPERIMENTAL
Intervention: Telazorlimab 600 mg every 2 weeks (part 2)
Number of subjects: 462
Study 38187863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (part 1)
Number of subjects: 462
Study 38187863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (part 2)
Number of subjects: 462
Study 38188047 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for care intensity allocation
Number of subjects: 0
Study 38188047 — intervention group
Group type: COMPARATOR
Intervention: Multi-professional care team for care intensity allocation
Number of subjects: 0
Study 38188262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine counseling in ICU recovery clinics (ICU-RCs)
Number of subjects: 32
Study 38188275 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay mesh
Number of subjects: 480
Study 38188275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublay mesh
Number of subjects: 480
Study 38188275 — intervention group
Group type: COMPARATOR
Intervention: Primary suture
Number of subjects: 480
Study 38188333 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory 'A'rt-Based Activity
Number of subjects: 112
Study 38188333 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 38188343 — intervention group
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Number of subjects: 0
Study 38188343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38188344 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thermotherapy via an electric heat pad in the thorax (target temperature range 39.5–42°C) continuously for 90 minutes, twice daily, for 5 days
Number of subjects: 105
Study 38188344 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study 38188467 — intervention group
Group type: EXPERIMENTAL
Intervention: TQB2450 (1-30 mg/kg, intravenous once every 3 weeks)
Number of subjects: 40
Study 38188539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg)
Number of subjects: 40
Study 38188539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 38188690 — intervention group
Group type: EXPERIMENTAL
Intervention: Leritrelvir 400 mg TID for 5 days
Number of subjects: 1359
Study 38188690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1359
Study 38188690 — intervention group
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Number of subjects: 1359
Study 38189125 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to community-based rehabilitation (physical, occupational, or speech therapy) at discharge
Number of subjects: 10702
Study 38189125 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to physical therapy
Number of subjects: 10702
Study 38189125 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to occupational therapy
Number of subjects: 10702
Study 38189125 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to speech therapy
Number of subjects: 10702
Study 38189125 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level predictors of referral
Number of subjects: 10702
Study 38189125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital referral rates
Number of subjects: 10702
Study 38189125 — intervention group
Group type: EXPERIMENTAL
Intervention: County-level predictor
Number of subjects: 10702
Study 38189180 — intervention group
Group type: EXPERIMENTAL
Intervention: sasanlimab plus BCG (induction ± maintenance)
Number of subjects: 1000
Study 38189180 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 1000
Study 38189182 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based caregiving (MBC)
Number of subjects: 279
Study 38189182 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 279
Study 38189492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B supplementation
Number of subjects: 984
Study 38189492 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 984
Study 38189593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 4535
Study 38189593 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 4535
Study 38189593 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate
Number of subjects: 4535
Study 38189649 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU subjective mental health assessment
Number of subjects: 855
Study 38189649 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU subjective functional health assessment
Number of subjects: 855
Study 38189649 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 855
Study 38189649 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 855
Study 38189649 — intervention group
Group type: EXPERIMENTAL
Intervention: Time after discharge
Number of subjects: 855
Study 38189764 — intervention group
Group type: EXPERIMENTAL
Intervention: Image Guided Programming (IGP)
Number of subjects: 32
Study 38189764 — intervention group
Group type: COMPARATOR
Intervention: Clinical Standard Care (CSC)
Number of subjects: 32
Study 38189778 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA and FLU-QIV (Co-Ad group)
Number of subjects: 885
Study 38189778 — intervention group
Group type: COMPARATOR
Intervention: FLU-QIV (SA group)
Number of subjects: 885
Study 38189778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Co-Ad and SA)
Number of subjects: 885
Study 38189853 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative telehealth call
Number of subjects: 126
Study 38189853 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 38189868 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement (TAR)
Number of subjects: 282
Study 38189868 — intervention group
Group type: COMPARATOR
Intervention: Ankle Fusion (AF)
Number of subjects: 282
Study 38189973 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometric exam
Number of subjects: 708
Study 38189999 — intervention group
Group type: EXPERIMENTAL
Intervention: Early D/LT group (patients who died or had undergone LT within 1 year after KP, n=35)
Number of subjects: 112
Study 38189999 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who survived through the native liver more than 1 year after KP, n=49)
Number of subjects: 112
Study 38189999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on independent variables (age at KP, jaundice clearance speed 1 month after KP, early-onset PC, sex, APRI, weight at KP)
Number of subjects: 112
Study 38189999 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier (K-M) curve
Number of subjects: 112
Study 38190001 — intervention group
Group type: EXPERIMENTAL
Intervention: Taldefgrobep alfa
Number of subjects: 0
Study 38190001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38190027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ocular pain group
Number of subjects: 38
Study 38190027 — intervention group
Group type: COMPARATOR
Intervention: No chronic ocular pain group
Number of subjects: 38
Study 38190051 — intervention group
Group type: EXPERIMENTAL
Intervention: Older paternal age (≥30 years)
Number of subjects: 16114
Study 38190051 — intervention group
Group type: COMPARATOR
Intervention: Paternal age <30 years
Number of subjects: 16114
Study 38190054 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS intervention program
Number of subjects: 100
Study 38190077 — intervention group
Group type: EXPERIMENTAL
Intervention: PP1M (fixed-dose, 50, 75, 100, or 150 mg eq.)
Number of subjects: 296
Study 38190077 — intervention group
Group type: EXPERIMENTAL
Intervention: PP3M (fixed-dose, 175, 263, 350, or 525 mg eq.)
Number of subjects: 296
Study 38190077 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CGI-S total score
Number of subjects: 296
Study 38190077 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in PANSS and CGI-S scores at week 13
Number of subjects: 296
Study 38190077 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization criteria
Number of subjects: 296
Study 38190119 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher predonation BMI
Number of subjects: 1042
Study 38190119 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference (WC)
Number of subjects: 1042
Study 38190136 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (60 mg per day for 2 days, followed by 20 mg per day for 5 days) in addition to standard therapy (oral mono or dual antiplatelet therapy)
Number of subjects: 628
Study 38190136 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 628
Study 38190136 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 628
Study 38190136 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 628
Study 38190202 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0
Study 38190202 — intervention group
Group type: COMPARATOR
Intervention: Non-Physical Activity (non-PA) days
Number of subjects: 0
Study 38190226 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback version of the e-12HR app
Number of subjects: 71
Study 38190226 — intervention group
Group type: COMPARATOR
Intervention: Nonfeedback version of the e-12HR app
Number of subjects: 71
Study 38190242 — intervention group
Group type: EXPERIMENTAL
Intervention: RE-PACT intervention (action planning, rapid clinical response, weekly SMS text messaging surveillance)
Number of subjects: 90
Study 38190242 — intervention group
Group type: EXPERIMENTAL
Intervention: RE-PACT intervention
Number of subjects: 90
Study 38190242 — intervention group
Group type: COMPARATOR
Intervention: Usual care through the complex care clinical program
Number of subjects: 90
Study 38190278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal counseling on the maternal health benefits of lactation
Number of subjects: 0
Study 38190278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prenatal counseling)
Number of subjects: 0
Study 38190338 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-of-Resistance (LOR) technique
Number of subjects: 117
Study 38190338 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Pressure-Sensing (DPS) technology
Number of subjects: 117
Study 38190492 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38190578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) added to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo)
Number of subjects: 160
Study 38190578 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo) without Bevacizumab (B)
Number of subjects: 160
Study 38190582 — intervention group
Group type: EXPERIMENTAL
Intervention: FoundationOne Liquid Companion Diagnostic (F1LCDx) assay
Number of subjects: 269
Study 38190582 — intervention group
Group type: COMPARATOR
Intervention: Standard tissue testing
Number of subjects: 269
Study 38190582 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS ctDNA analysis
Number of subjects: 269
Study 38190582 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based NGS ctDNA assay
Number of subjects: 269
Study 38190642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r) oral solution
Number of subjects: 28
Study 38190701 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Molecular Injury at Diagnosis of Acute Cellular Rejection
Number of subjects: 0
Study 38190832 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin + rituximab + lenalidomide (Pola+R+Len)
Number of subjects: 57
Study 38190964 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping with active release technique for 4 weeks (3 days/week)
Number of subjects: 32
Study 38190964 — intervention group
Group type: COMPARATOR
Intervention: Kinesio taping alone for 4 weeks (5 days/week)
Number of subjects: 32
Study 38191014 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach
Number of subjects: 604
Study 38191014 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure messaging outreach
Number of subjects: 604
Study 38191014 — intervention group
Group type: COMPARATOR
Intervention: Mailed letter outreach
Number of subjects: 604
Study 38191203 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric telemedicine service (TMDS)
Number of subjects: 391
Study 38191245 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment including reduction and fixation of the syndesmosis
Number of subjects: 120
Study 38191245 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment with an orthosis
Number of subjects: 120
Study 38191245 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 120
Study 38191245 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 120
Study 38191246 — intervention group
Group type: EXPERIMENTAL
Intervention: SKYPE programme (physiotherapy, yoga, and patient education)
Number of subjects: 0
Study 38191246 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 38191248 — intervention group
Group type: EXPERIMENTAL
Intervention: MABC clinics
Number of subjects: 441
Study 38191249 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Activity Scoring Tool (FAST)
Number of subjects: 0
Study 38191249 — intervention group
Group type: COMPARATOR
Intervention: Patient-Specific Functional Scale (PSFS)
Number of subjects: 0
Study 38191249 — intervention group
Group type: COMPARATOR
Intervention: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 0
Study 38191249 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Rating of Change (GROC) scale
Number of subjects: 0
Study 38191268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 202
Study 38191268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 38191317 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI Brasil app (provides information about PIP, therapeutic alternatives and deprescribing)
Number of subjects: 146
Study 38191317 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI Brasil app
Number of subjects: 146
Study 38191317 — intervention group
Group type: COMPARATOR
Intervention: MedSUS app (provides general information about medications)
Number of subjects: 146
Study 38191317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 38191318 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital test battery from Mindmore
Number of subjects: 50
Study 38191318 — intervention group
Group type: COMPARATOR
Intervention: Analog test battery from ISPOCD
Number of subjects: 50
Study 38191347 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical high-flow nasal cannula (Optiflow® Duet system)
Number of subjects: 20
Study 38191347 — intervention group
Group type: COMPARATOR
Intervention: Standard high-flow nasal cannula
Number of subjects: 20
Study 38191370 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS (intermittent theta burst stimulation)
Number of subjects: 230
Study 38191370 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 230
Study 38191370 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label low-frequency right-sided (1 Hz) stimulation
Number of subjects: 230
Study 38191406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive interactive, professionally facilitated, 8- to 10-h Sanyas ICS training
Number of subjects: 58
Study 38191406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief 1-h anti-bias training adapted to address anti-Indigenous bias
Number of subjects: 58
Study 38191406 — intervention group
Group type: COMPARATOR
Intervention: Control continuing medical education time-attention matched to the intensive training
Number of subjects: 58
Study 38191436 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no treatment
Number of subjects: 1397
Study 38191436 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified treatment receiving 1 sachet of RUTF daily until WAZ ≥-3 for 2 visits
Number of subjects: 1397
Study 38191436 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment receiving RUTF according to WHZ category
Number of subjects: 1397
Study 38191449 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 mg (3 tablets daily) for 6 weeks
Number of subjects: 110
Study 38191449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets daily) for 6 weeks
Number of subjects: 110
Study 38191529 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 × 19 CAR-T cells
Number of subjects: 39
Study 38191536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical test (FIT) outreach and patient navigation program
Number of subjects: 28
Study 38191536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach supported by clinics, health plans, and vendors
Number of subjects: 28
Study 38191561 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (AcoArt Orchid)
Number of subjects: 244
Study 38191561 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon catheter
Number of subjects: 244
Study 38191589 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Pilates (TP)
Number of subjects: 32
Study 38191589 — intervention group
Group type: COMPARATOR
Intervention: Nontraditional Pilates (NTP)
Number of subjects: 32
Study 38191613 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy followed by four cycles of atezolizumab plus docetaxel, oxaliplatin and capecitabine
Number of subjects: 21
Study 38191613 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy
Number of subjects: 21
Study 38191615 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus nab-paclitaxel (n = 353)
Number of subjects: 531
Study 38191615 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel (n = 178)
Number of subjects: 531